AKT1 and ovarian carcinoma: Clinically, PI3K/AKT signaling is highly activated in ovarian cancer, and vast preclinical studies and clinical data suggested that inhibitors of PI3K/AKT pathway exerted an antitumor efficiency in the treatment of ovarian cancer (22).